On May 6, 2026, GSK plc held its 26th Annual General Meeting where all 25 resolutions, including the approval of the 2025 Annual Report and the election of four directors, passed with overwhelming support (over 96% approval). The total votes cast represented 76.38% of its issued share capital, reinforcing shareholder confidence.